3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
7
Gynecologic
2
Breast
2
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
10
Nivolumab
5
Gemcitabine
4
durvalumab
3
Specimen Handling
3
Sirolimus
3
Magnetic Resonance Spectroscopy
3
Docetaxel
3
Cryosurgery
3
Cisplatin
3
Blood Specimen Collection
3
tremelimumab
2
temsirolimus
2
pertuzumab
2
pegilodecakin
2
enzalutamide
2
cabozantinib
2
alvocidib
2
Vorinostat
2
Trastuzumab
2
Ritonavir
2
Radiotherapy
2
Radiosurgery
2
Psychiatric Rehabilitation
2
Paclitaxel
2
Oxaliplatin
2
Interleukin-2
2
Cyclophosphamide
2
Carboplatin
2
Biopsy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Genetic Counseling
×
Dermatologic
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled